SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05163080 |
Recruitment Status :
Active, not recruiting
First Posted : December 20, 2021
Last Update Posted : February 26, 2024
|
Sponsor:
MimiVax, LLC
Collaborators:
Translational Drug Development
Merit
Information provided by (Responsible Party):
MimiVax, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 18, 2024 |
Estimated Study Completion Date : | August 18, 2024 |
Publications of Results: